VIVUS Inc. (NASDAQ:VVUS)’s first quarter 2014 loss (excluding one-time items) of 13 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 53 cents. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.25 moved to $5.95 on last trade day and at the end of the day closed at $5.57. Company price to sales ratio in past twelve months was calculated as 7.10 and price to cash ratio as 1.68. VIVUS, Inc. (NASDAQ:VVUS) showed a positive weekly performance of 10.08%.
Celldex Therapeutics (NASDAQ:CLDX) announced its earnings results on Thursday. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.25) by $0.08, Analyst RN reports. The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.34 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. The company’s quarterly revenue was down 83.3% on a year-over-year basis. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares fell -6.56% in last trading session and ended the day on $13.10. CLDX return on equity ratio is recorded as -38.40% and its return on assets is -34.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) yearly performance is 2.50%.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced that the Company will host a conference call and live audio webcast with an accompanying slide presentation at 8:00 a.m. EDT on Tuesday, May 13, 2014 to report its first quarter 2014 financial results. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares moved down -4.59% in last trading session and was closed at $2.70, while trading in range of $2.66 – $2.90. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) year to date (YTD) performance is -41.68%.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism announced that it will host a conference call and live webcast on Thursday, May 8, 2014, at 8:30 a.m. EDT to report its first quarter 2014 financial results and discuss recent business activities. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) weekly performance is 2.59%. On last trading day company shares ended up $42.40. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) distance from 50-day simple moving average (SMA50) is 5.52%. Analysts mean target price for the company is $58.00.